299964-35-5

Basic information

• Product Name: (+/-)-2-bromo-1-(4-benzyloxy-3-nitrophenyl)ethanol
• Synonyms: (+/-)-2-bromo-1-(4-benzyloxy-3-nitrophenyl)ethanol
• CAS NO: 299964-35-5
• Molecular Weight: 352.184
• Mol File: 299964-35-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (+/-)-2-bromo-1-(4-benzyloxy-3-nitrophenyl)ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: (+/-)-2-bromo-1-(4-benzyloxy-3-nitrophenyl)ethanol(299964-35-5)
• EPA Substance Registry System: (+/-)-2-bromo-1-(4-benzyloxy-3-nitrophenyl)ethanol(299964-35-5)

Safety Data

• Hazardous Substances Data: 299964-35-5(Hazardous Substances Data)

Usage

Description

(+/-)-2-bromo-1-(4-benzyloxy-3-nitrophenyl)ethanol is a chemical compound with the molecular formula C14H14BrNO4. It is a brominated compound containing a benzyl and nitro group attached to an ethanol backbone.
Used in Pharmaceutical Industry:
(+/-)-2-bromo-1-(4-benzyloxy-3-nitrophenyl)ethanol is used as a building block for the preparation of various drugs. Its presence in the compound makes it suitable for a wide range of applications in organic chemistry.
Used in Organic Synthesis:
(+/-)-2-bromo-1-(4-benzyloxy-3-nitrophenyl)ethanol is used as a precursor for the preparation of biologically active compounds. It can act as a building block for the preparation of other organic molecules.

Upstream product

• 100-44-7 benzyl chloride 
• 99-93-4 4-Hydroxyacetophenone 
• 6322-56-1 4'-hydroxy-3'-nitroacetophenone 
• 43229-01-2 4-benzyloxy-3-nitrophenacyl bromide 
• 14347-05-8 4-benzyloxy-3-nitroacetophenone 

Downstream Products

• 1361398-74-4 N-(5-(2-(benzyl(2-(4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-hexahydrophthalazin-2(1H)-yl)ethyl)amino)-1-hydroxyethyl)-2-(benzyloxy)phenyl)formamide 
• 1361398-75-5 N-(5-(2-(benzyl(2-(4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-hexahydrophthalazin-2(1H)-yl)butyl)amino)-1-hydroxyethyl)-2-(benzyloxy)phenyl)formamide 
• 1361398-76-6 N-(5-(2-(benzyl(2-(4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-hexahydrophthalazin-2(1H)-yl)pentyl)amino)-1-hydroxyethyl)-2-(benzyloxy)phenyl)formamide 
• 1361398-77-7 N-(5-(2-(benzyl(2-(4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-hexahydrophthalazin-2(1H)-yl)hexyl)amino)-1-hydroxyethyl)-2-(benzyloxy)phenyl)formamide 
• 1361398-78-8 N-(5-(2-((2-(4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-hexahydrophthalazin-2(1H)-yl)ethyl)amino)-1-hydroxyethyl)-2-hydroxyphenyl)formamide 
• 1361398-79-9 N-(5-(2-((2-(4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-hexahydrophthalazin-2(1H)-yl)butyl)amino)-1-hydroxyethyl)-2-hydroxyphenyl)formamide 
• 1361398-80-2 N-(5-(2-((2-(4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-hexahydrophthalazin-2(1H)-yl)pentyl)amino)-1-hydroxyethyl)-2-hydroxyphenyl)formamide 
• 1361398-81-3 N-(5-(2-((2-(4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-hexahydrophthalazin-2(1H)-yl)hexyl)amino)-1-hydroxyethyl)-2-hydroxyphenyl)formamide 
• 1218777-34-4 5-(4-(benzyloxy)-3-nitrophenyl)oxazolidin-2-one 
• 51582-41-3 2-(3-benzyloxy-4-nitrophenyl)oxirane 
• 408497-91-6 N-(2-Benzyloxy-5-{(R)-1-hydroxy-2-[(R)-2-(4-methoxy-phenyl)-1-methyl-ethylamino]-ethyl}-phenyl)-formamide 
• 245759-61-9 (R)-1-(4-Benzyloxy-3-nitro-phenyl)-2-[(R)-2-(4-methoxy-phenyl)-1-methyl-ethylamino]-ethanol 
• 299964-43-5 (R)-1-(3-Amino-4-benzyloxy-phenyl)-2-[(R)-2-(4-methoxy-phenyl)-1-methyl-ethylamino]-ethanol 
• 73573-87-2 (R,R)-formoterol 

Relevant articles and documents

Design, synthesis and evaluation of dual pharmacology β2- adrenoceptor agonists and PDE4 inhibitors

A novel series of formoterol-phthalazinone hybrids were synthesised and evaluated as dual pharmacology β2-adrenoceptor agonists and PDE4 inhibitors. Most of the hybrids displayed high β2-adrenoceptor agonist and moderate PDE4 inhibitory activities. The most potent compound, (R,R)-11c, exhibited agonist (EC50 = 1.05 nM, pEC50 = 9.0) and potent PDE4B2 inhibitory activities (IC50 = 0.092 μM).

An efficient enantioselective synthesis of (R,R)-formoterol, a potent bronchodilator, using lipases

The potent β2-adrenergic receptor agonist formoterol (R,R)-1 has been obtained in enantiomerically pure form by a convenient chemoenzymatic approach by coupling of epoxide (R)-6 with the unprotected primary amine (R)-9. Both chiral precursors have been prepared by enantiodifferentiation processes involving Pseudomonas cepacia (lipase PS) and Candida antarctica lipase (CALB), respectively. For the resolution of amine 9, we have found that utilization of triethylamine as non-reactive base enhances the reaction rate and the enantioselectivity of the process. The key coupling reaction of (R)-6 and (R)-9 has been conducted through derivatization of the amine with the labile trimethylsilyl group, which liberates the amino group of the resulting amino alcohol (R,R)-11 upon column chromatography purification. In this way, the overall approach is shorter than others previously described. Copyright (C) 2000 Elsevier Science Ltd.

Bronchospasmolytic phenylethanolamines

Phenylethanolamines of the formula I STR1 wherein R is substituted phenyl or optionally substituted furyl, thienyl, or pyridyl, R5 is hydrogen, lower alkyl, or optionally substituted benzyl, R4, R6, R8, and Rsu